Arthritic Therapeutic Market Outlook Through 2030: Understanding The Growth Opportunity

Arthritic Therapeutic Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Arthritic Therapeutic Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The arthritic therapeutic market size has experienced substantial expansion in recent years. It will grow from $72.44 billion in 2025 to $77 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. This historical growth can be attributed to a global increase in arthritis prevalence, a growing geriatric population, restricted access to advanced therapeutics, enhanced awareness of arthritis management, and the expansion of hospital and clinic infrastructure.

The arthritic therapeutic market size is anticipated to experience substantial growth in the coming years. This market is projected to reach $97.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. The expansion during the forecast period can be attributed to the development of novel biologics and targeted therapies, the increasing adoption of telemedicine and remote patient monitoring, the integration of digital health platforms, rising investment in arthritis research and clinical trials, and the growth in personalized medicine approaches for arthritis. Major trends in the forecast period include the rising adoption of biologic and targeted therapies for arthritis, an increasing preference for personalized arthritis management plans, the growth in home-based physical therapy and rehabilitation services, the expansion of online pharmacies and digital distribution channels, and an increasing focus on early diagnosis and preventive arthritis care.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19297&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Arthritic Therapeutic Market Growth Drivers: What’s Behind The Acceleration?

The rising occurrence of arthritis is anticipated to stimulate expansion in the arthritic therapeutic market in the future. Arthritis encompasses over 100 conditions primarily marked by pain and swelling in the joints. The prevalence of arthritis is escalating due to an aging demographic, higher obesity levels, and lifestyle choices that lead to joint strain and inflammation. Therapies for arthritis aim to ease discomfort, reduce swelling, and restore joint mobility, thereby improving the general well-being of individuals affected. For example, in June 2024, a report from the Australian Institute of Health and Welfare, an Australia-based government organization, indicated that around 514,000 people (2.0% of the population) were afflicted with rheumatoid arthritis in 2022. Rheumatoid arthritis constituted 2.0% of the overall disease burden and accounted for 16% of the total burden for all musculoskeletal conditions in 2023. Consequently, the increasing incidence of arthritis is fueling the growth of the arthritic therapeutic market.

Arthritic Therapeutic Market Segment Analysis And Revenue Potential

The arthritic therapeutic market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Type: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab

2) By Interleukin Inhibitors: Interleukin-6 (IL-6) Inhibitors, Interleukin-1 (IL-1) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors

3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam

4) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

5) By Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat

6) By Other Drug Classes: Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic DMARDs, Topical Analgesics, Opioid Pain Medications

Arthritic Therapeutic Market Trends: What’s Defining The Industry’s Next Phase?

Major companies operating in the arthritis therapeutic market are concentrating on developing innovative solutions, such as biosimilar monoclonal antibody-based therapies, to enhance the effectiveness of treatments and reduce associated costs. These biosimilar monoclonal antibody-based therapies are medical interventions crafted to closely replicate and imitate the efficacy of original monoclonal antibodies, thereby offering similar therapeutic advantages at a potentially lower price. As an illustration, in May 2024, Bio-Thera Solutions Ltd., a biopharmaceutical company located in China, introduced TOFIDENCE, an intravenous biosimilar monoclonal antibody formulation based on ACTEMRA. TOFIDENCE (tocilizumab-bavi) has been developed as a biosimilar to the reference drug ACTEMRA and has gained approval for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Arthritic Therapeutic Market Key Players Shaping Industry Direction

Major companies operating in the arthritic therapeutic market are Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Pharma AB, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Incyte Corporation, Celltrion Inc., Mallinckrodt Pharmaceuticals, Genentech Inc., Anika Therapeutics Inc., Medac GmbH

View The Full Arthritic Therapeutic Market Report:

https://www.thebusinessresearchcompany.com/report/arthritic-therapeutic-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Arthritic Therapeutic Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the arthritic therapeutic market in 2025. The regions covered in the arthritic therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model